Breaking News

Glycovax Pharma Commercializes a More Affordable CRM197 Protein

Glycovax has refined its production to meet regulatory requirements and will market the protein through its subsidiary Espoir Therapeutics.

By: Rachel Klemovitch

Assistant Editor

Glycovax Pharma Inc. has begun large-scale biomanufacturing of the CRM197 protein for use in numerous conjugate vaccines for human and animal vaccines. The company will market this protein through its subsidiary, Espoir Therapeutics Inc., to meet the needs of vaccine development companies and research centers in the sector. Glycovax has refined its production to meet regulatory requirements and standards for conjugate vaccine components for human and animal administration. The National Re...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters